Last reviewed · How we verify
In-stent restenosis
At a glance
| Generic name | In-stent restenosis |
|---|---|
| Sponsor | Silesian Centre for Heart Diseases |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Compare the Effectiveness and Safety of Two Different Kinds of Cutting Balloon in Coronary Artery Disease (NA)
- A Real-world Study to Evaluate the Primary Patency and Freedom From TLR of Endovascular Treatment in TOSAKA III In-stent Restenosis of Lower Extremity Femoropopliteal Artery.
- A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) (PHASE3)
- A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) - Long Lesion Cohort (PHASE3)
- Predictors and Long-term Incidence of In-stent Restenosis After Chronic Total Occlusion Percutaneous Coronary Intervention (NA)
- MIRAGE Study: Clinical Outcomes of the Mamba Sirolimus-Eluting PTCA Balloon (PHASE4)
- Coronary Artery Drug-Coated Balloon Dilatation Catheter Clinical Trial Protocol
- The PICCOLETO XI A-PREP Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- In-stent restenosis CI brief — competitive landscape report
- In-stent restenosis updates RSS · CI watch RSS
- Silesian Centre for Heart Diseases portfolio CI